Hepatocellular carcinoma (HCC) is the most frequent liver malignancy and the fourth most common cause of cancer-related death worldwide. Mortality from these tumours occurs primarily due to late detection. As the diagnosis and screening of HCC currently relies on advanced imaging modalities, many patients are not screened and thus diagnosed at late stages of disease which precludes potentially curative surgical intervention. Our collaboration with Fujirebio opens new avenues for developing and implementing standardized clinical tests which will be able to identify patients with early stages of HCC.
There is a clear clinical need for accessible and reliable parameters to identify high-risk populations in order to decrease the high mortality rates. Since diagnosis mainly occurs during late stage disease only one third of the diagnosed patients is eligible for curative treatments. If we will be able to identify predictors for HCC development we would be able to diagnose patients earlier which would immensely increase treatment options and life expectancy.
Within our project we will work on serum biomarkers which could serve as a non-invasive tool for surveillance and early diagnosis of HCC. We will test the performance of a broad set of relevant serological markers in a large cohort of serum samples obtained from patients who developed HCC as a consequence of different etiologies (HBV, HCV, alcohol, non-alcoholic steatohepatitis (NASH) etc.), but also from patients at risk, or patients with liver diseases without known HCC presence. Improving our knowledge about serum markers could lead to early diagnosis of HCC as well as better and earlier treatment strategies for this deadly disease.
In the first 6 months we will test the set of markers in a liver disease cohort. In the following year we will test the markers in selected HCC cohorts. Lastly we will validate our findings in a high-risk cohort.
Type the project impact here.